Aurinia Pharmaceuticals (AUPH) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.23
- Estimate
- $0.22
- Surprise
- +4.5%
- Revenue (period 2026-09-30)
- $83.7M
- Score at report (before → after)
- 6.9 → 6.2/10
Revenue source: xbrl.
How the report landed
Aurinia Pharmaceuticals (AUPH) beat the $0.22 estimate with adjusted EPS of $0.23 — a clear 4.5% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.9/10) to Hold at 6.2/10 after the report — the engine's score fell despite the beat.
Where TrendMatrix's rating stands now
TrendMatrix currently rates AUPH Buy (Wait) at 6.2/10.
4 of the last 4 quarters beat the estimate; this quarter's +4.5% surprise compares with a +163.5% four-quarter average. Next scheduled report: 2027-03-01.
What supports the rating
- V7 crisis quality shield: -0.3 vs -1.5 (Q=8.7)
- Sector modifier (Healthcare): +0.8
What argues against it
- Cyclical risk: PE expanding 2.0x (earnings normalizing)
- Thin upside margin: 9.5%
- Negative momentum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $14.70
- Entry target
- $14.02
- Price target
- $16.09
- Stop
- $13.04
- Upside to target
- +9.5%
- Reward-to-risk
- 1.4:1
Forward estimates sit below the trailing run-rate (12.8× forward vs 6.5× trailing) — consensus expects earnings to decline from here.
Model outputs from TrendMatrix’s engine as of 2026-11-20 — shown for context, not personalized investment advice.
AUPH at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.00B
- P/E (fwd)
- 12.8
- P/E (ttm)
- 6.5
- 52-week range
- $13.52–$19.25
- Off 52-week high
- 23.6%
- RSI (14)
- 33
- Volume vs avg
- 1.37×
- Score today
- 6.2/10